Chongqing Zhifei Biological Products Co., Ltd.

SZSE:300122 Stock Report

Market Cap: CN¥67.4b

Chongqing Zhifei Biological Products Future Growth

Future criteria checks 4/6

Chongqing Zhifei Biological Products is forecast to grow earnings and revenue by 43.1% and 13.9% per annum respectively. EPS is expected to grow by 41.1% per annum. Return on equity is forecast to be 18.9% in 3 years.

Key information

43.1%

Earnings growth rate

41.1%

EPS growth rate

Biotechs earnings growth43.7%
Revenue growth rate13.9%
Future return on equity18.9%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well

Nov 26
These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Sep 30
Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Sep 03
Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Aug 23
Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Jul 26
We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

May 21
Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Apr 26
Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Mar 26
Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Earnings and Revenue Growth Forecasts

SZSE:300122 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202646,1228,63611,0729,7988
12/31/202551,7709,6396,7388,66512
12/31/202432,2013,3121,98613,5252
9/30/202436,4323,6902,3313,346N/A
6/30/202446,7316,0445,5006,512N/A
3/31/202453,1417,4964,6655,763N/A
12/31/202352,9188,0707,8628,996N/A
9/30/202349,7128,4622,4763,586N/A
6/30/202344,3568,0704,3575,546N/A
3/31/202340,5967,6482,9514,266N/A
1/1/202338,2647,5395361,989N/A
9/30/202236,6477,412-3601,175N/A
6/30/202235,8358,447-1,151596N/A
3/31/202235,56711,1933,4525,305N/A
12/31/202130,65210,2096,5758,508N/A
9/30/202125,9699,2267,5159,350N/A
6/30/202121,3687,2878,0509,627N/A
3/31/202116,4823,7232,6913,868N/A
12/31/202015,1903,3012,6703,497N/A
9/30/202013,9713,0822,5543,272N/A
6/30/202012,5422,7241,0381,604N/A
3/31/202010,9282,3816911,318N/A
12/31/201910,5872,3667941,367N/A
9/30/20199,4002,1285981,145N/A
6/30/20198,1951,916247764N/A
3/31/20196,6841,694-42282N/A
12/31/20185,2281,451106586N/A
9/30/20184,0681,234-32698N/A
6/30/20182,969943N/A170N/A
3/31/20182,019632N/A298N/A
12/31/20171,343432N/A204N/A
9/30/2017942311N/A207N/A
6/30/2017707192N/A126N/A
3/31/201746434N/A87N/A
12/31/201644633N/A90N/A
9/30/201643144N/A253N/A
6/30/2016512101N/A207N/A
3/31/2016660209N/A265N/A
12/31/2015713197N/A223N/A
9/30/2015779172N/A143N/A
6/30/2015805160N/A165N/A
3/31/2015835153N/A167N/A
12/31/2014801148N/A161N/A
9/30/2014777136N/A153N/A
6/30/2014735124N/A179N/A
3/31/2014758132N/A157N/A
12/31/2013780130N/A222N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300122's forecast earnings growth (43.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 300122's earnings (43.1% per year) are forecast to grow faster than the CN market (25.8% per year).

High Growth Earnings: 300122's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300122's revenue (13.9% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 300122's revenue (13.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300122's Return on Equity is forecast to be low in 3 years time (18.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 07:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chongqing Zhifei Biological Products Co., Ltd. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xin ZhangAJ Securities Co., Ltd
Bo LiBofA Global Research
Yuanrui LiuChangjiang Securities Co. LTD.